参考文献:
[1]YANG SZ, FENG XB, DONG JH. Surgical treatment of liver cancer guided by the concept of precision surgery[J]. J Pre Med, 2018, 33(3): 189-192, 196. (in Chinese)
杨世忠, 冯晓彬, 董家鸿. 精准外科理念指导下的肝癌外科治疗[J]. 精准医学杂志, 2018, 33(3): 189-192, 196.
[2]CHEN Z, WANG J. Consideration in the diagnosis and treatment of hepatic cancer based onevidence-based guidelines and precision medicine[J]. Lingnan Mod Clin Surg, 2018, 18(6): 615-617. (in Chinese)
陈政, 王捷. 基于循证指南和精准医学时代背景下肝癌诊疗的思考与总结[J]. 岭南现代临床外科, 2018, 18(6): 615-617.
[3]LU SC, GU WQ. Essentials of precision medicine in practice of surgical oncology for hepatobiliary tumors[J]. Chin J Hepatobiliary Surg, 2019, 25(1): 1-4. (in Chinese)
卢实春, 顾万清. 肝胆肿瘤外科治疗精准医学概要[J]. 中华肝胆外科杂志, 2019, 25(1): 1-4.
[4]SCHULZE K, NAULT JC, VILLANUEVA A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing[J]. J Hepatol, 2016, 65(5): 1031-1042.
[5]FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
[6]GAO Q, ZHU H, DONG L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J]. Cell, 2019, 179(5): 1240.
[7]European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[8]HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380.
[9]LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359: 378-390.
[10]SCHULZE K, IMBEAUD S, LETOUZ E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J]. Nat Genet, 2015, 47(5): 505-511.
[11]GYAWALI B, PRASAD V. Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC[J]. Nat Rev Clin Oncol, 2017, 14(11): 653-654.
[12]SAWEY ET, CHANRION M, CAI C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening[J]. Cancer Cell, 2011, 19(3): 347-358.
[13]VILGRAIN V, PEREIRA H, ASSENAT E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1624-1636.
[14]CHENG AL, KANG YK, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[15]BRUIX J, RAOUL JL, SHERMAN M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial[J]. J Hepatol, 2012, 57(4): 821-829.
[16]MARRERO JA, KUDO M, VENOOK AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study[J]. J Hepatol, 2016, 65(6): 1140-1147.
[17]FINN RS, MERLE P, GRANITO A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial[J]. J Hepatol, 2018, 69(2): 353-358.
[18]KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[19]CAINAP C, QIN S, HUANG WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial[J]. J Clin Oncol, 2015, 33(2): 172-179.
[20]CHENG AL, KANG YK, LIN DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial[J]. J Clin Oncol, 2013, 31(32): 4067-4075.
[21]BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66.
[22]KELLEY RK, VERSLYPE C, COHN AL, et al. Cabozantinib in hepatocellular carcinoma: Results of a phase 2 placebo-controlled randomized discontinuation study[J]. Ann Oncol, 2017, 28(3): 528-534.
[23]ABOU-ALFA GK, MEYER T, CHENG AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med, 2018, 379(1): 54-63.
[24]HEINRICH S, CASTVEN D, GALLE PR, et al. Translational considerations to improve response and overcome therapy resistance in immunotherapy for hepatocellular carcinoma[J]. Cancers (Basel), 2020, 12(9): e2495.
[25]SANGRO B, GOMEZ-MARTIN C, de la MATA M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol, 2013, 59(1): 81-88.
[26]ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952.
[27]EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
[28]FINN RS, RYOO BY, MERLE P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial[J]. J Clin Oncol, 2020, 38(3): 193-202.
[29]REBOUISSOU S, LA BELLA T, REKIK S, et al. Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro[J]. Clin Cancer Res, 2017, 23(15): 4364-4375.
[30]HU Z, OTT PA, WU CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer[J]. Nat Rev Immunol, 2018, 18(3): 168-182.
[31]NEELAPU SS, LOCKE FL, GO WY. CAR T-cell therapy in large B-cell lymphoma[J]. N Engl J Med, 2018, 378(11): 1065.
[32]NEELAPU SS, TUMMALA S, KEBRIAEI P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1): 47-62.
[33]PARK R, ESHRAT F, AL-JUMAYLI M, et al. Immuno-oncotherapeutic approaches in advanced hepatocellular carcinoma[J]. Vaccines (Basel), 2020, 8(3): e447.
[34]PENG L, BIAN XW, LI DK, et al. Large-scale RNA-Seq transcriptome analysis of 4043 cancers and 548 normal tissue controls across 12 TCGA cancer types[J]. Sci Rep, 2015, 5: 13413.
[35]FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[36]FINN RS, IKEDA M, ZHU AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970.
[37]KELLEY RK, W OLIVER J, HAZRA S, et al. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design[J]. Future Oncol, 2020, 16(21): 1525-1536.
[38]GUARDASCIONE M, TOFFOLI G. Immune checkpoint inhibitors as monotherapy or within a combinatorial strategy in advanced hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21(17): e6302.
[39]FENG GS, HANLEY KL, LIANG Y, et al. Improving the efficacy of liver cancer immunotherapy: The power of combined preclinical and clinical studies[J]. Hepatology, 2020. [Online ahead of print]
[40]ZHU XD, LI KS, SUN HC. Adjuvant therapies after curative treatments for hepatocellular carcincma: Current status and prospects[J]. Genes Dis, 2020, 7(3): 359-369.
[41]CANALE M, ULIVI P, FOSCHI FG, et al. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma[J]. Crit Rev Oncol Hematol, 2018, 129: 44-53.
[42]ZHU HB, ZENG PH, GAO WH, et al. Discussion on the treatment of hepatocarcinoma with the multi-disciplinary integrated treatment team model combining traditional Chinese medicine and western medicine[J]. Guid J Tradit Chin Med Pharmacol, 2019, 25(22): 21-24, 31. (in Chinese)
朱洪兵, 曾普华, 郜文辉, 等. 中西医联合MDT模式在肝癌治疗中的探讨[J]. 中医药导报, 2019, 25(22): 21-24, 31.
[43]CHUMA M, UOJIMA H, NUMATA K, et al. Early changes in circulating FGF19 and Ang-2 levels as possible predictive biomarkers of clinical response to lenvatinib therapy in hepatocellular carcinoma[J]. Cancers (Basel), 2020, 12(2): 293.
[44]LEE JJX, CHAN JJ, CHOO SP. Clinical development of c-MET inhibition in hepatocellular carcinoma[J]. Diseases, 2015, 3(4): 306-324.
[45]RIMASSA L, ABBADESSA G, PERSONENI N, et al. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib[J]. Oncotarget, 2016, 7(45): 72622-72633.
[46]JIANG Y, SUN A, ZHAO Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma[J]. Nature, 2019, 567(7747): 257-261.